Investor's Business Daily on MSN13h
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly BeatSanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Head of Investor Relations Welcome to the Q3 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide number 3. Here we have the usual ...
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback